Page last updated: 2024-11-04

pargyline

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pargyline is a non-selective, irreversible inhibitor of monoamine oxidase (MAO), an enzyme that breaks down neurotransmitters like dopamine, norepinephrine, and serotonin. It was originally developed as an antihypertensive agent but is no longer widely used for this purpose due to its potential for serious side effects, such as hypertensive crisis. However, it remains a research tool for studying the role of MAO in various neurological and psychiatric conditions. Pargyline is synthesized through a multi-step process involving the reaction of propargyl bromide with an amine. It is known to have a range of effects, including:
* Increasing the levels of monoamines in the brain.
* Inhibiting the breakdown of tyramine, a compound found in certain foods, which can lead to hypertensive crisis.
* Possessing potential antidepressant activity.
* Showing promise in treating Parkinson's disease and Alzheimer's disease.
* Being investigated for its potential in treating other neurological conditions, such as anxiety and addiction.
Pargyline is studied because of its unique pharmacological profile and its potential to provide insights into the role of MAO in various diseases. Its ability to inhibit both MAO-A and MAO-B makes it a valuable research tool for investigating the complex interactions between these enzymes and neurotransmitter systems. However, its clinical use is limited due to its potential for serious side effects, which necessitates careful monitoring and management.'

Pargyline: A monoamine oxidase inhibitor with antihypertensive properties. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4688
CHEMBL ID673
CHEBI ID7930
SCHEMBL ID2045
MeSH IDM0015951

Synonyms (120)

Synonym
a 19120
AKOS009027469
BRD-K83597974-003-05-7
KBIO1_000053
DIVK1C_000053
n-methyl-n-(phenylmethyl)prop-2-yn-1-amine
eutron
n-methyl-n-benzylpropynylamine
pargylamine
benzylmethylpropargylamine
ccris 6740
brn 1938132
pargylinum [inn-latin]
paragyline
n-methyl-n-2-propynylbenzylamine
benzyl-methyl-2-propinylamin [czech]
einecs 209-101-6
pargyline [inn:ban]
pargilina [inn-spanish]
n-methyl-n-propargylbenzylamine
ai3-62058
n-benzyl-n-methyl-2-propynylamine
supirdyl
SPECTRUM_000641
IDI1_000053
NCGC00015841-02
NCGC00015841-01
cas-306-07-0
lopac-p-8013
CBCHROMO1_000308
BSPBIO_002159
LOPAC0_001022
SPECTRUM5_001030
mo 911
eutonyl
n-methyl-n-(2-propynyl)benzylamine-
benzenemethanamine, n-methyl-n-2-propynyl-
n-benzyl-n-methyl-2-propyn-1-amine
methylbenzylpropynylamine
2-propynylamine, n-benzyl-n-methyl-
n-benzyl-n-methyl-prop-2-yn-1-amine
benzylamine, n-methyl-n-2-propynyl-
eudatin
benzylmethylpropynylamine
AB00053516
C07414
555-57-7
pargyline
n-methyl-n-propargylbenzylamine, 97%
DB01626
KBIO2_003689
KBIOSS_001121
KBIO2_001121
KBIO2_006257
KBIOGR_000918
KBIO3_001659
SPECTRUM4_000469
PRESTWICK0_000183
SPBIO_001257
NINDS_000053
SPECTRUM3_000540
SPBIO_002026
PRESTWICK1_000183
SPECTRUM2_001039
PRESTWICK3_000183
PRESTWICK2_000183
BPBIO1_000117
BSPBIO_000105
NCGC00024240-03
NCGC00015841-03
NCGC00015841-07
chebi:7930 ,
CHEMBL673 ,
pargyline (inn)
D08453
n-benzyl-n-methylprop-2-yn-1-amine
benzyl-methyl-prop-2-ynyl-amine
bdbm50172756
dpwpwrlqfgfjfi-uhfffaoysa-
inchi=1/c11h13n/c1-3-9-12(2)10-11-7-5-4-6-8-11/h1,4-8h,9-10h2,2h3
CCG-205102
NCGC00015841-06
NCGC00015841-05
NCGC00015841-04
pargylin
2-12-00-00548 (beilstein handbook reference)
pargilina
unii-9mv14s8g3e
benzyl-methyl-2-propinylamin
9mv14s8g3e ,
pargylinum
benzyl(methyl)(prop-2-yn-1-yl)amine
gtpl7262
pargyline [who-dd]
pargyline [mi]
pargyline [vandf]
pargyline [inn]
SCHEMBL2045
CS-4685
n-benzyl-n-methyl-2-propinylamine
W-105554
n-benzyl-n-methyl-2-propyn-1-amine #
pargyline hydrochloride (salt/mix)
eutonyl (salt/mix)
HY-A0091A
HMS3604I04
AB00053516_13
DTXSID3023423
SBI-0050995.P004
M2618
FT-0700064
Z103710848
n-methyl-n-(2-propyn-1-yl)benzylamine
Q781329
EN300-120295
SDCCGSBI-0050995.P005
NCGC00015841-18
T72610
AS-75650
mfcd00008576

Research Excerpts

Overview

Pargyline is a lipophilic amine with a low pKa-value of 6.6 and undergoes extensive metabolism. It is a potentially valuable ligand for the estimation of the concentration of NAO active centres.

ExcerptReferenceRelevance
"[3H]-Pargyline is a potentially valuable ligand for the estimation of the concentration of NAO active centres without the need to remove the enzyme from the mitochondrial membrane."( The binding of [3H] pargyline to rat liver mitochondrial monoamine oxidase.
Callingham, BA; Parkinson, D, 1980
)
1.04
"Pargyline is a lipophilic amine with a low pKa-value of 6.6 and undergoes extensive metabolism."( The metabolic fate of pargyline in rat liver microsomes.
Lindeke, B; Weli, AM, 1985
)
1.31

Effects

ExcerptReferenceRelevance
"[3H]Pargyline has been covalently linked to active sites of both type A and type B monoamine oxidase (MAO) obtained from various tissues. "( Studies on the pargyline-binding site of different types of monoamine oxidase.
Yu, PH, 1981
)
1.17

Actions

Pargyline was found to inhibit binding of spin labeled amphetamine by cytosolic monoamine oxidase. It did not increase the reinforcement rate at low doses that selectively inhibit MAO-B, but did increase it at doses that inhibit MAo-A by more than 90%.

ExcerptReferenceRelevance
"Pargyline was found to inhibit binding of spin labeled amphetamine by cytosolic monoamine oxidase."( Interaction between cytosolic monoamine oxidase and spin-labeled amphetamine and its modification by clorgyline and pargyline.
Campbell, IC; Copeland, ES; Murphy, DL, 1983
)
1.2
"Pargyline did not increase the reinforcement rate at low doses that selectively inhibit MAO-B, but did increase the reinforcement rate at doses that inhibit MAO-A by more than 90%."( Selective inhibition of MAO-A, not MAO-B, results in antidepressant-like effects on DRL 72-s behavior.
Marek, GJ; Seiden, LS, 1988
)
1

Treatment

Pargyline in vivo treatment (100 mg/kg i.p.) caused a complete inhibition of the low Km-AldDH activity of the matrix fraction. Treatment alone resulted in a significant elevation of the concentration of dopamine in pituitary stalk plasma.

ExcerptReferenceRelevance
"Oral pargyline treatment protected transplanted beta cells in diabetic mice, thus leading to disease reversal."( Genome-scale in vivo CRISPR screen identifies RNLS as a target for beta cell protection in type 1 diabetes.
Cai, EP; Hollister-Lock, J; Hou, S; Ishikawa, Y; Kiaf, B; Kissler, S; Leite, NC; Li, J; Melton, DA; Schiffer, CA; Yi, P; Yilmaz, NK; Zhang, W, 2020
)
1.01
"Pargyline treatment reduced the magnitude of V(d) globally to 34-54 ml g(-1)."( Effect of monoamine oxidase inhibition on amphetamine-evoked changes in dopamine receptor availability in the living pig: a dual tracer PET study with [11C]harmine and [11C]raclopride.
Cumming, P; Jensen, SB; Olsen, AK; Pedersen, K, 2006
)
1.06
"The pargyline pretreated rats exposed to acute stress exhibited a significant increase in adrenal catecholamine content and COMT activity with no change in TH and phenylethanolamine-N-emthyl transferase (PNMT) activity as compared to normal stressed rats."( Catecholamine metabolism in pargyline treated rats exposed to stress.
Chansouria, JP; Patel, V; Prasad, R; Udupa, KN, 1980
)
1.04
"2) Pargyline in vivo treatment (100 mg/kg i.p.) caused a complete inhibition of the low Km-AldDH activity of the matrix fraction but caused only a 10% inhibition of the high Km-AldDH activities of the matrix and the outer membrane fractions."( Effects of pargyline and diethyldithiocarbamate in vivo treatment on aldehyde dehydrogenase activities of submitochondrial fractions.
Nakanishi, S; Nishiguchi, K; Saladin, R; Yamazaki, H, 1980
)
1.16
"Pargyline treatment alone resulted in a significant elevation of the concentration of dopamine in pituitary stalk plasma and a reduction in the serum concentration of prolactin."( Function of tuberoinfundibular dopamine neurons in pargyline- and reserpine-treated rats.
Gudelsky, GA; Meltzer, HY, 1984
)
1.24
"Pargyline treatment caused an increase in the DA concentrations in the anterior lobe by about 150%."( Regional differences in the effect of pargyline on dopamine concentrations in the rat hypophysis.
Cohen, G; Cooper, T; Holzbauer, M; Krause, U; Mann, SP; Racké, K; Sharman, DF, 1984
)
1.26
"In pargyline treated rats, 17 h after denervation, noradrenaline stores were 90% of control glands."( Electron microscopic evidence that bretylium and pargyline delay adrenergic nerve degeneration after sympathectomy of the pineal gland.
Gomez-Dumm, GL; Perec, CJ; Sanz, NR; Stefano, FJ, 1982
)
1.03
"In pargyline-pretreated rats, TB produced a decrease of brain NE with an increase of normetanephrine, while the action of RES was weaker than that of TB, up to 2 hr."( Effects of tricyclic antidepressants on tetrabenazine-induced depletion of brain monoamines in rats. 1. Norepinephrine.
Tonda, K; Yoshizaki, T, 1980
)
0.78
"In pargyline pretreated preparations, the order of potency of a number of tryptamine analogues was as follows: 5-MeO-T > or = alpha-Me-5-HT > or = 5-HT > 5-carboxamidotryptamine (5-CT) > tryptamine > 2-Me-5-HT."( Further characterization of 5-hydroxytryptamine receptors (putative 5-HT2B) in rat stomach fundus longitudinal muscle.
Baxter, GS; Blackburn, TP; Murphy, OE, 1994
)
0.8
"In pargyline-pretreated subjects, both dopamine and epinephrine significantly suppressed food intake, at doses as low as 31 ng for dopamine and 150 ng for epinephrine (the latter injected with an alpha-adrenoceptor blocker)."( Analysis of feeding suppression produced by perifornical hypothalamic injection of catecholamines, amphetamines and mazindol.
Leibowitz, SF; Rossakis, C, 1978
)
0.77
"In pargyline pretreated male rats, an intraventricular 6-hydroxydopamine procedure which resulted in subtotal brain catecholamine (CA) depletion produced a mild defict in copulatory behavior followed by rapid recovery. "( Interactive effects of brain catecholamines and variations in sexual and non-sexual arousal on copulatory behavior of male rats.
Antelman, M; Caggiula, AR; Edwards, DJ; Shaw, DH, 1976
)
0.88
"Pargyline or reserpine treatment of male rats during the first two weeks of life resulted in significantly increased exploratory activity (sniffing) associated with a significantly decreased emotional reactivity (defecation rate) in adult life. "( Further evidence of permanent behavioural changes in rats treated neonatally with neurodrugs.
Dörner, G, 1976
)
1.7
"Pargyline pretreatment increased the fluorescence of axons and SIF cells but did not reveal a different distribution of these structures.(ABSTRACT TRUNCATED AT 250 WORDS)"( Distribution of catecholamine-containing nerves on blood vessels of the rat trachea.
Baker, DG; McDonald, DM, 1992
)
1
"Pargyline pretreatment in the presence of imipramine, infused through the dialysis probe, slowly increased 5-HT levels above that produced by the reuptake blocker alone."( Characterization of monoamine release in the lateral hypothalamus of awake, freely moving rats using in vivo microdialysis.
Basbaum, AI; Matos, FF; Rollema, H, 1990
)
1
"Pargyline pretreatment 2 h before ischemia had marginal effects on the postischemic clearing of dopamine."( Effects of transient forebrain ischemia and pargyline on extracellular concentrations of dopamine, serotonin, and their metabolites in the rat striatum as determined by in vivo microdialysis.
Boisvert, DP; Damsma, G; Fibiger, HC; Mudrick, LA; Wenkstern, D, 1990
)
1.26
"Pargyline treatment (75 mg/kg i.p., 4 h prior to sacrifice) increased catecholamine levels in spinal cord, hypothalamus, and brainstem."( Effect of monoamine oxidase inhibition on catecholamine levels: evidence for synthesis but not storage of epinephrine in rat spinal cord.
Sved, AF, 1990
)
1
"Pargyline pretreatment prevented the loss of striatal dopamine and cells from the substantia nigra, but did not prevent a prolonged but reversible decrease in the concentration of dopamine metabolites."( Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the dog: effect of pargyline pretreatment.
Bacon, JP; Burns, RS; Chiueh, CC; Garrick, NA; Johannessen, JN; Kopin, IJ; Markey, SP; Parisi, JE; Weise, VK, 1989
)
1.23
"Pargyline pretreatment, however, resulted in consecutive elimination of 11C-MPTP-derived radioactivity from the different brain regions with half-lives of 40-60 min."( Influence of monoamine oxidase inhibitors and a dopamine uptake blocker on the distribution of 11C-N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 11C-MPTP, in the head of the rhesus monkey.
Gullberg, P; Hartvig, P; Långström, B; Larsson, BS; Lindberg, BS; Lindquist, NG; Lundqvist, H; Malmborg, P; Oreland, L; Rimland, A, 1986
)
0.99
"In pargyline-treated colons, serotonin-like fibres were demonstrated in association with either the small intramural blood vessels of the submucosa or the extramural nerve bundles."( An immunohistochemical study of serotonin-containing nerves in the colon of rats.
Nada, O; Toyohara, T, 1987
)
0.79
"Pargyline treatment decreased [3H]tryptamine binding in cerebral cortex, hippocampus, striatum and hypothalamus."( Effects of pargyline, reserpine and neurotoxin lesions on [3H]tryptamine binding sites in rat brain.
Cascio, CS; Kellar, KJ, 1986
)
1.38
"In pargyline-pretreated rats, 50 and 150 micrograms DA caused marked suppression, but 15 micrograms DA caused enhancement."( Effects on the caudate spindle in rats of dopamine microinjected into the caudate nucleus.
Aihara, H; Hashimoto, S; Okuyama, S, 1985
)
0.78
"1 Pargyline treatment, 1 h before (+)-amphetamine (1 mg/kg), reduced amphetamine-stimulated motor activity. "( Evidence for involvement of 5-hydroxytryptamine in the actions of amphetamine.
Breese, GR; Cooper, BR; Mueller, RA, 1974
)
0.97
"Treatment with pargyline significantly induced cell cycle arrest at the G1 phase compared to the control and tranylcypromine-treated cells."( Effects of the monoamine oxidase inhibitors pargyline and tranylcypromine on cellular proliferation in human prostate cancer cells.
Chai, YG; Choi, MR; Doh, MS; Jung, KH; Lee, HT, 2013
)
0.99
"Pretreatment with pargyline attenuated the MPTP-induced clinical signs, MRI and MRS changes, and the histopathological and immunoreactivity alterations."( Proton magnetic resonance imaging and spectroscopy identify metabolic changes in the striatum in the MPTP feline model of parkinsonism.
Hadjiconstantinou, M; Neff, NH; Podell, M; Smith, MA, 2003
)
0.64
"Treatment with pargyline, an inhibitor of monoamine oxidase, lowered the t-MIAA levels in all regions."( Regional distribution of the histamine metabolite, tele-methylimidazoleacetic acid, in rat brain: effects of pargyline and probenecid.
Green, JP; Hough, LB; Khandelwal, JK, 1984
)
0.82
"Treatment with pargyline (512 mumoles/kg) or bretylium (24 mumoles/kg) significantly delayed the loss of noradrenaline from denervated glands."( Electron microscopic evidence that bretylium and pargyline delay adrenergic nerve degeneration after sympathectomy of the pineal gland.
Gomez-Dumm, GL; Perec, CJ; Sanz, NR; Stefano, FJ, 1982
)
0.86
"Treatment with pargyline significantly increased the incidence of colon tumors in week 35."( Monoamine oxidase B inhibitor enhances experimental carcinogenesis in rat colon induced by azoxymethane.
Baba, M; Iishi, H; Taniguchi, H; Tatsuta, M, 1994
)
0.63
"Treatment with pargyline alone increased the extracellular dopamine concentration by 70% in the striatum and by 140% in the substantia nigra and induced in both regions a time-dependent accumulation of 3-methoxytyramine."( 3-Methoxytyramine formation following monoamine oxidase inhibition is a poor index of dendritic dopamine release in the substantia nigra.
Bergquist, F; Elverfors, A; Jonason, J; Lagerkvist, S; Nissbrandt, H; Pileblad, E, 1997
)
0.64
"Pretreatment with pargyline increased their recoveries, whereas alpha-methyldopa (an L-aromatic amino acid decarboxylase enzyme inhibitor, L-AAADI) decreased them considerably, and no significant alteration was found in L-alpha-methyldopa hydrazine (a peripheral L-AAADI) pretreated animals."( Pathways linking L-phenylalanine and 2-phenylethylamine with p-tyramine in rabbit brain.
Mosnaim, AD; Silkaitis, RP, 1976
)
0.58
"Pretreatment with pargyline abolished these metabolic increases, a finding suggesting both that the oxidized product of MPTP generates the metabolic increases and that the increased glucose consumption may contribute to cell toxicity."( Cerebral metabolic effects of monoamine oxidase inhibition in normal and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine acutely treated monkeys.
Bankiewicz, KS; Crane, AM; Kopin, IJ; Palombo, E; Porrino, LJ; Sokoloff, L, 1991
)
0.6
"Pretreatment with pargyline, a monoamine oxidase inhibitor, did not alter the mortality but prevented dopamine depletion."( Effects of internal carotid administration of MPTP on rat brain and blood-brain barrier.
Dietrich, WD; Harik, SI; Riachi, NJ, 1990
)
0.6
"Pretreatment with pargyline, an agent which prevents the metabolism of MPTP to the 1-methyl-4-phenylpyridinium ion (MPP+), did not potentiate or antagonize the magnitude of this aversion."( Pargyline and naltrexone fail to antagonize the gustatory avoidance response induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
DeVito, MJ; Wagner, GC, 1986
)
2.04
"Pretreatment with pargyline and tryptophan increased the amount of serotonin immunoreactivity in tissue fixed with Pf-G but not in tissue fixed with Pf."( The effects of different pretreatment conditions and fixation regimes on serotonin immunoreactivity: a quantitative light microscopic study.
Beitz, AJ; Clements, JR, 1985
)
0.59
"Treatment with pargyline plus tropolone caused a 100-200% increase in noradrenaline output; this effect was not modified by cocaine, but was abolished when the tissues were pretreated with either phenoxybenzamine or corticosterone.7."( Evaluation of mechanisms controlling the release and inactivation of the adrenergic transmitter in the rabbit portal vein and vas deferens.
Hughes, J, 1972
)
0.59

Toxicity

ExcerptReferenceRelevance
" The toxic effects of the tetrahydropyridines and their corresponding pyridiniums were both concentration- and time-dependent."( 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine- and 1-methyl-4-(2'-ethylphenyl)-1,2,3,6-tetrahydropyridine-induced toxicity in PC12 cells: role of monoamine oxidase A.
Basma, AN; Geller, HM; Giovanni, A; Heikkila, RE; Nicklas, WJ, 1990
)
0.28
" These results support the concept that AAM is oxidatively deaminated by an SSAO present in vascular cells to generate toxic metabolic by-products capable of causing extensive cellular injury."( Allylamine-induced vascular toxicity in vitro: prevention by semicarbazide-sensitive amine oxidase inhibitors.
Cox, LR; Grossman, SL; Ramos, K, 1988
)
0.27
" MPTP was more toxic to hepatocytes than its major metabolite, 1-methyl-4-phenylpyridine (MPP+); this may, in part, be explained by the lesser permeability of the hepatocyte plasma membrane to the cation compared to its parent compound, MPTP."( The mechanism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity: role of intracellular calcium.
Kass, GE; Nicotera, P; Orrenius, S; Wright, JM, 1988
)
0.27
" Thus formation of a toxic metabolite by the action of MAO B may be involved in DSP-4 induced neural damage."( Inhibition of MAO B, but not MAO A, blocks DSP-4 toxicity on central NE neurons.
Gibson, CJ, 1987
)
0.27
" Experiments were designed to determine whether central catecholaminergic systems are implicated in the toxic and lethal manifestations of soman toxicity and whether the protection afforded by clonidine involves such pathways."( Role of central biogenic amines on the protection afforded by clonidine against the toxicity of soman, an irreversible cholinesterase inhibitor.
Aronstam, RS; Buccafusco, JJ; Graham, JH, 1988
)
0.27
" The results are compatible with the view that the monoamine oxidase-catalyzed conversion of MPTP to a toxic metabolite MPP+ occurs mainly extraneuronally."( Differential time course of protection by monoamine oxidase inhibition and uptake inhibition against MPTP neurotoxicity on central catecholamine neurons in mice.
Jonsson, G; Sundström, E, 1986
)
0.27
" Addition of MPP+ itself is toxic to hepatocytes but only after a long lag period, which presumably reflects its limited access to the cell and its relatively slow intracellular accumulation."( Role of 1-methyl-4-phenylpyridinium ion formation and accumulation in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity to isolated hepatocytes.
Castagnoli, N; Di Monte, D; Ekström, G; Shinka, T; Smith, MT; Trevor, AJ, 1987
)
0.27
" After administration of toxic doses of MPTP, the concentration of MPP+ in the substantia nigra appears to increase during the first 72 hours, reaching the highest concentration of any central nervous system (CNS) tissue studied."( Selective accumulation of MPP+ in the substantia nigra: a key to neurotoxicity?
Irwin, I; Langston, JW, 1985
)
0.27
" When animals were pretreated with inhibitors of alcohol metabolism followed by a testicular toxic dose of EGME (500 mg/kg), an inhibitor of alcohol dehydrogenase (pyrazole) offered complete protection."( Testicular toxicity produced by ethylene glycol monomethyl and monoethyl ethers in the rat.
Creasy, DM; Foster, JR; Foster, PM; Gray, TJ, 1984
)
0.27
"Prior studies concluded that 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, a toxin causing parkinsonism) and its analogues are bioactivated by monoamine oxidase (MAO) to toxic pyridinium metabolites."( Suppression of hydroxyl radical formation by MAO inhibitors: a novel possible neuroprotective mechanism in dopaminergic neurotoxicity.
Chiueh, CC; Huang, SJ; Murphy, DL, 1994
)
0.29
" For toxic doses (5 microM), the loss of GSH preceded the onset of toxicity by six hr."( The role of glutathione in the toxicity of a novel cyanobacterial alkaloid cylindrospermopsin in cultured rat hepatocytes.
Ge, JL; Kong, SM; Lu, SC; Runnegar, MT; Zhong, YZ, 1994
)
0.29
" precursor, arginine, was increased significantly in the brain by toxic O2 exposure, but both pargyline and LNNA inhibited this effect."( Cerebral amino acid, norepinephrine and nitric oxide metabolism in CNS oxygen toxicity.
Oury, TD; Piantadosi, CA; Su, Y; Zhang, J, 1993
)
0.51
" We have assessed the toxic effects of dopamine and L-DOPA toward catecholaminergic neuroblastoma SH-SY5Y cells and whether R(-)-deprenyl and several structurally related compounds possess antioxidant effects in this system."( R(-)-deprenyl potentiates dopamine-induced cytotoxicity toward catecholaminergic neuroblastoma SH-SY5Y cells.
Lai, CT; Yu, PH, 1997
)
0.3
"The ability of allylamine (AA) administration to produce vascular lesions resembling atherosclerotic disease in animals, has been linked to metabolism of AA to the toxic aldehyde acrolein (ACR) by a semicarbazide-sensitive amine oxidase (SSAO) found in plasma and in vascular smooth muscle."( [Effect of activity of semicarbazide-sensitive aminooxidases and cellular glutathione on the cytotoxic effect of allylamine, acrolein, and formaldehyde in human cultured endothelial cells].
Lyles, GA; Pino, R,
)
0.13
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Compound-Compound Interactions

ExcerptReferenceRelevance
"The objective of the study was to evaluate the metabolism dependent inhibition of CYP2B6 catalyzed bupropion hydroxylation in human liver microsomes by monoamine oxidase (MAO) inhibitors and to predict the drug-drug interaction potential of monoamine oxidase inhibitors as perpetrators of drug interaction."( Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction.
Bhyrapuneni, G; Manoharan, A; Mohammed, AR; Nirogi, R; Palacharla, RC; Ponnamaneni, RK, 2015
)
0.42

Bioavailability

ExcerptReferenceRelevance
" This model of peripheral aromatization was utilized to evaluate in vivo pharmacological parameters of MDL 18,962 (10-(2-propynyl)estr-4-ene-3,17-dione) such as bioavailability of several formulations, time course and dose responses following different routes of drug administration, pharmacokinetics and tissue distribution of [14C]MDL 18,962."( Human trophoblast xenografts in athymic mice: a model for peripheral aromatization.
Johnston, JO; Shumaker, RC; Wright, CL, 1989
)
0.28
"A novel unsymmetrical structural class of orally bioavailable hepatitis C virus (HCV) nonstructural 5A protein (NS5A) inhibitors has been generated by improving both the solubility and membrane permeability of the lead compound found in our previous work."( Orally bioavailable HCV NS5A inhibitors of unsymmetrical structural class.
Akagi, Y; Fujioka, S; Inaba, T; Ito, S; Kinoshita, W; Komoda, Y; Kondo, K; Maeda, K; Nakamura, H; Okuda, S; Tamatani, Y; Terui, T; Ukaji, Y, 2020
)
0.56

Dosage Studied

Pargyline is a non-selective inhibitor of monoamine oxidase. Shifting the PCA dose-response curve for inducing the 5-HT behavioural syndrome to the left.

ExcerptRelevanceReference
" Cocaine or phentolamine shifted the dose-response curve to the left."( Effects of ethylephrine on the rat atrial pacemaker.
Aramendía, P; De Mikulic, LE; Márquez, MT, 1977
)
0.26
"0 mg/kg) attenuated, in a dose-response fashion, the induction of stereotyped behavior and hyperactivity by pargyline (0."( Testosterone-attenuated stereotype and hyperactivity induced by beta-phenylethylamine in pargyline-pretreated rats.
Freemark, M; Gillin, JC; Moja, EA; Stoff, DM; Wyatt, RJ, 1978
)
0.69
" For higher initial contractions relaxation is slowed during the first minute of wash out, probably because of the sigmoid shape of the dose-response curve."( Relaxation of splenic strips during wash out with amine-free solution after an exposure to noradrenaline.
Lindmark, E; Schlör, G; Trendelenburg, U, 1976
)
0.26
"We studied the dose-response and the time-course effect of beta-phenylethylamine (4."( Dose-response effects of beta-phenylethylamine on stereotyped behavior in pargyline-pretreated rats.
Gillin, JC; Moja, EA; Stoff, DM; Wyatt, RJ, 1976
)
0.49
" Treatment of reserpinized rats with pargyline, a non-selective inhibitor of monoamine oxidase, in order to increase cerebral 5-HT levels, shifts the PCA dose-response curve for inducing the 5-HT behavioural syndrome to the left."( 5-Hydroxytryptamine release in vivo from a cytoplasmic pool: studies on the 5-HT behavioural syndrome in reserpinized rats.
Kuhn, DM; Wolf, WA; Youdim, MB, 1985
)
0.54
" To determine if TMT altered monoamine turnover or metabolite efflux, mice were dosed with 0 or 3 mg/kg TMT; 2 weeks later, pargyline (75 mg/kg, intraperitoneally) was administered and the mice sacrificed 0, 30 and 60 min."( Cholinergic and dopaminergic alterations in the mouse central nervous system following acute trimethyltin exposure.
Ali, SF; Goad, PT; Newport, GD; Slikker, W, 1986
)
0.48
" Our results show that TRM induced both the depression and excitation in the behavior of mice depending on the dosage and TRM-induced excitatory behaviors may be attributed to both its direct stimulation of 5-HT receptors and facilitation of 5-HT release."( Effect of tryptamine on the behavior of mice.
Horisaka, K; Sugimoto, Y; Yamada, J, 1986
)
0.27
" Pargyline in the dosage used is known to be a non-selective MAO inhibitor and it prevented the metabolism of 11C-MPTP to the products retained in the brain."( Influence of monoamine oxidase inhibitors and a dopamine uptake blocker on the distribution of 11C-N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 11C-MPTP, in the head of the rhesus monkey.
Gullberg, P; Hartvig, P; Långström, B; Larsson, BS; Lindberg, BS; Lindquist, NG; Lundqvist, H; Malmborg, P; Oreland, L; Rimland, A, 1986
)
1.18
" Pargyline and tranylcypromine shifted the dose-response curves for tyramine and beta-phenylethylamine, but not serotonin, to the left, indicating inhibition of type B MAO."( Some cardiovascular effects of monoamine oxidase inhibitors in unanaesthetized rats.
Huston, V; Marwood, JF; Wall, KT,
)
1.04
" When given in combination with d,l-5-HTP, there was a potentiation of the down-regulation capabilities of fenfluramine at several different dosage levels; however, maximal down-regulation was also limited to 40%."( Down-regulation of [3H]5-hydroxytryptamine binding sites in chick embryo brain by monoamine oxidase inhibitors or fenfluramine and potentiation by d,l-5-hydroxytryptophan.
DuMontier, G; Jeng, I; Soblosky, JS, 1985
)
0.27
" The dose-response relationship for hyperactivity in grouped mice following the injection of morphine sulphate has been established."( Monoamine mediation of the morphine-induced activation of mice.
Carroll, BJ; Sharp, PT, 1972
)
0.25
" A non-anorectic dosage of L110-140 (3."( The role of norepinephrine in feeding behavior.
Davies, RF; Panksepp, J; Rossi, J; Zolovick, AJ, 1982
)
0.26
" In the present study we determined the time-course and dose-response effects of 6-MeO-THbetaC for blockade of AGS."( Effects of 6-methoxy-1,2,3,4-tetrahydro-beta-carboline (6-MeO-THbetaC) on audiogenic seizures in DBA/2J mice.
Buckholtz, NS; Sparks, DL, 1980
)
0.26
" In fact, a sigmoid-shaped dose-response curve was generated by plotting either the lordosis quotient or quality score versus the percent increase in preoptic-hypothalamic 5HT."( Effects of monoamine oxidase inhibition on female sexual behavior, serotonin levels and type A and B monoamine oxidase activity.
Luine, VN; Paden, CM, 1982
)
0.26
" The loss of inward current in the region of negative slope conductance is dose-dependent, highly reproducible and relatively resistant to desensitization, and for these reasons a valid dose-response relationship can be described."( Dopamine inhibits burst-firing of neurosecretory cell R 15 in Aplysia californica: establishment of a dose-response relationship.
Gospe, SM; Wilson, WA, 1980
)
0.26
" At a sub-effective dose, pargyline could cause a leftward shift in the dose-response curve of 5-HTP-induced antinociception."( L-type calcium channel blockers enhance 5-HTP-induced antinociception in mice.
Chen, B; Han, R; Li, JX; Liang, JH; Lu, Y; Wang, XH; Ye, XF; Zhang, P, 2004
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic amineAn amino compound in which the amino group is linked directly to an aromatic system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
phenylethylamine degradation I220
superpathway of phenylethylamine degradation939

Protein Targets (33)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thyroid stimulating hormone receptorHomo sapiens (human)Potency4.03460.001318.074339.8107AID926
arylsulfatase AHomo sapiens (human)Potency7.56861.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency26.67950.035520.977089.1251AID504332
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency5.01190.65619.452025.1189AID927
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency0.63100.031610.279239.8107AID884; AID885
lamin isoform A-delta10Homo sapiens (human)Potency8.91250.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)Potency5.01191.584913.004325.1189AID927
GABA theta subunitRattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency0.63101.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency37.93300.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpRattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.40002.75008.6000AID1209456
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1209455; AID1449628
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)IC50 (µMol)1.53500.00040.764912.5000AID1639479; AID289285
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)Ki0.03490.00081.09276.0000AID1192621; AID1192622
Amine oxidase [flavin-containing] A Rattus norvegicus (Norway rat)IC50 (µMol)390.20000.00071.979812.5000AID289284
Amine oxidase [flavin-containing] A Rattus norvegicus (Norway rat)Ki0.02030.00190.55334.8000AID1192621
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)6.91360.00002.37899.7700AID1230937; AID1319664; AID1332147; AID1365630; AID1373671; AID1378328; AID1378345; AID1416361; AID1484641; AID1528913; AID1571214; AID1624337; AID1626714; AID1632838; AID1754860; AID1891688; AID751624; AID771513
Amine oxidase [flavin-containing] BHomo sapiens (human)IC50 (µMol)0.50310.00001.89149.5700AID1057002; AID1190179; AID1230939; AID1231602; AID1332148; AID1347963; AID1365631; AID1373672; AID1378329; AID1378346; AID1416360; AID1528914; AID1556047; AID1570043; AID1571215; AID1594619; AID1624338; AID1626716; AID1632839; AID1649992; AID1663416; AID1694875; AID1754859; AID1761229; AID1868506; AID1891689; AID434137; AID729965; AID771522
Amine oxidase [flavin-containing] BHomo sapiens (human)Ki0.62330.00061.777110.0000AID1192621; AID1192622; AID254307
ReninCallithrix jacchus (white-tufted-ear marmoset)IC50 (µMol)2.60000.08003.12676.7000AID434137
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Amine oxidase [flavin-containing] BHomo sapiens (human)Kd0.27540.00900.11930.2754AID1192631
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)EC50 (µMol)1.00000.00540.42203.2000AID1769259
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (91)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
response to xenobiotic stimulusAmine oxidase [flavin-containing] BHomo sapiens (human)
response to toxic substanceAmine oxidase [flavin-containing] BHomo sapiens (human)
response to aluminum ionAmine oxidase [flavin-containing] BHomo sapiens (human)
response to selenium ionAmine oxidase [flavin-containing] BHomo sapiens (human)
negative regulation of serotonin secretionAmine oxidase [flavin-containing] BHomo sapiens (human)
phenylethylamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
substantia nigra developmentAmine oxidase [flavin-containing] BHomo sapiens (human)
response to lipopolysaccharideAmine oxidase [flavin-containing] BHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to ethanolAmine oxidase [flavin-containing] BHomo sapiens (human)
positive regulation of dopamine metabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
hydrogen peroxide biosynthetic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to corticosteroneAmine oxidase [flavin-containing] BHomo sapiens (human)
proline biosynthetic processPyrroline-5-carboxylate reductase 1, mitochondrialHomo sapiens (human)
cellular response to oxidative stressPyrroline-5-carboxylate reductase 1, mitochondrialHomo sapiens (human)
regulation of mitochondrial membrane potentialPyrroline-5-carboxylate reductase 1, mitochondrialHomo sapiens (human)
L-proline biosynthetic processPyrroline-5-carboxylate reductase 1, mitochondrialHomo sapiens (human)
negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathwayPyrroline-5-carboxylate reductase 1, mitochondrialHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
lipid transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid biosynthetic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate metabolic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transmembrane transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transepithelial transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
renal urate salt excretionBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
export across plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular detoxificationBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (37)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
electron transfer activityAmine oxidase [flavin-containing] BHomo sapiens (human)
identical protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
pyrroline-5-carboxylate reductase activityPyrroline-5-carboxylate reductase 1, mitochondrialHomo sapiens (human)
protein bindingPyrroline-5-carboxylate reductase 1, mitochondrialHomo sapiens (human)
identical protein bindingPyrroline-5-carboxylate reductase 1, mitochondrialHomo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ABC-type xenobiotic transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
efflux transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP hydrolysis activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATPase-coupled transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
identical protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein homodimerization activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (30)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial envelopeAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] BHomo sapiens (human)
dendriteAmine oxidase [flavin-containing] BHomo sapiens (human)
neuronal cell bodyAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionPyrroline-5-carboxylate reductase 1, mitochondrialHomo sapiens (human)
mitochondrial matrixPyrroline-5-carboxylate reductase 1, mitochondrialHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
nucleoplasmBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
brush border membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
mitochondrial membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
membrane raftBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
external side of apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (223)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1132601Antidepressant activity in mouse assessed as antagonism of tetrabenazine-induced symptoms at 10 mg/kg, ip administered 30 mins before 35 mg/kg, ip tetrabenazine challenge measured after 30 mins by arousal test1978Journal of medicinal chemistry, Apr, Volume: 21, Issue:4
2-(Alkoxyaryl)-2-imidazoline monoamine oxidase inhibitors with antidepressant activity.
AID1589023Effect on tryptophan content in human SUM159PT cells at 100 uM by LC-MS analysis relative to control2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
A fragment-like approach to PYCR1 inhibition.
AID1694881Inhibition of recombinant human MAO- A using p-tyramine as substrate preincubated with enzyme for 15 mins followed incubation with substrate for 20 mins by Amplex red reagent based fluorescence based analysis2020RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2
Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
AID1651630Inhibition of equine serum BChE using (S)-butyrylthiocholine iodide as substrate at 10 uM measured for 6 mins by Ellman's method2020Journal of natural products, 04-24, Volume: 83, Issue:4
Bioactive Azepine-Indole Alkaloids from
AID34018Inhibition of the enzyme Alcohol dehydrogenase was measured in rats which are untreated with phenobarbital (PB)1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Metabolic depropargylation and its relationship to aldehyde dehydrogenase inhibition in vivo.
AID1261183Irreversible inhibition of human MAO-B expressed in baculovirus infected BT1 cells microsome fraction assessed as enzyme activity recovered at 10 times of IC50 concentration preincubated for 30 mins followed by dilution to 0.1 times of IC50 concentration 2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Monoamine oxidase inhibitory activities of heterocyclic chalcones.
AID1571229Irreversible inhibition of MAOB (unknown origin) assessed as residual enzyme activity at 0.2 uM using benzylamine as substrate measured after 30 mins relative to control2018MedChemComm, Nov-01, Volume: 9, Issue:11
Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors.
AID1754860Inhibition of human recombinant MAO-A using pargyline as incubated for 20 mins measuring increase in emission signal at 310 nm multimode plate reader assay2021Bioorganic & medicinal chemistry, 07-15, Volume: 42Synthesis and biological evaluation of 3-styrylchromone derivatives as selective monoamine oxidase B inhibitors.
AID1231602Inhibition of human recombinant MAO-B using benzylamine as substrate incubated for 15 mins prior to substrate addition measured after 20 mins by fluorescence plate reader analysis2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer's disease.
AID749467Induction of adipogenesis in human bone marrow MSC assessed as adiponectin production at 30 uM after 14 days by ELISA relative to control2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
The opposite effect of isotype-selective monoamine oxidase inhibitors on adipogenesis in human bone marrow mesenchymal stem cells.
AID1261182Irreversible inhibition of human MAO-A expressed in baculovirus infected BT1 cells microsome fraction assessed as enzyme activity recovered at 10 times of IC50 concentration preincubated for 30 mins followed by dilution to 0.1 times of IC50 concentration 2015Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
Monoamine oxidase inhibitory activities of heterocyclic chalcones.
AID1416360Inhibition of recombinant human MAO-B assessed as reduction in H2O2 production using p-tyramine as substrate preincubated for 15 mins followed by substrate addition by Amplex red reagent based fluorescence assay2017MedChemComm, Jul-01, Volume: 8, Issue:7
Synthesis and pharmacological evaluation of multi-functional homoisoflavonoid derivatives as potent inhibitors of monoamine oxidase B and cholinesterase for the treatment of Alzheimer's disease.
AID1589024Effect on valine content in human SUM159PT cells at 100 uM by LC-MS analysis relative to control2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
A fragment-like approach to PYCR1 inhibition.
AID1152191Reversible inhibition of recombinant human MAO-A using kynuramine as substrate assessed as enzyme residual activity at 4 times IC50 incubated for 15 mins measured after 24 hrs of dialysis by fluorescence spectrophotometry analysis relative to control2014Bioorganic & medicinal chemistry letters, Jun-15, Volume: 24, Issue:12
α-Tetralone derivatives as inhibitors of monoamine oxidase.
AID1589022Effect on leucine content in human SUM159PT cells at 100 uM by LC-MS analysis relative to control2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
A fragment-like approach to PYCR1 inhibition.
AID1484641Inhibition of recombinant human MAO-A using kynuramine as substrate by fluorescence spectroscopy2017European journal of medicinal chemistry, Jul-28, Volume: 135The evaluation of 1,4-benzoquinones as inhibitors of human monoamine oxidase.
AID729966Inhibition of recombinant human MAO-A using p-tyramine substrate preincubated for 15 mins before substrate addition measured after 20 mins by fluorescence assay2013European journal of medicinal chemistry, Apr, Volume: 62A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.
AID1663426Antialzheimer activity in scopolamine-induced impairment in ICR mouse assessed as total entries at 15 mg/kg, ip administered once a day for 10 days pretreated with scopolamine for 30 mins and measured at 5th day of training session by Morris water maze te2020Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12
Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
AID1570053Cognition enhancement in scopolamine-induced impairment in ICR mouse assessed as distance to target at 10 mg/kg, ip administered once daily for 2 weeks pretreated with scopolamine for 30 mins and measured at 5th day of training session by Morris water maz2019European journal of medicinal chemistry, Oct-15, Volume: 180Design, synthesis and biological evaluation of hydroxypyridinone-coumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer's disease.
AID189941T/C value of compound was measured in rats which are untreated with phenobarbital (PB)1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Metabolic depropargylation and its relationship to aldehyde dehydrogenase inhibition in vivo.
AID1868505Inhibition of human MAO-B using p-tyramine as substrate at 100 uM by fluorimetric analysis relative to control2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1868503Inhibition of human MAO-A using p-tyramine as substrate at 100 uM by fluorimetric analysis relative to control2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1740539Reversible inhibition of recombinant human MAOB expressed in baculovirus infected BTI insect cells assessed as recovery of enzyme activity at 10 times IC50 using p-tyramine as substrate preincubated for 30 mins followed by 100-fold dilution by Amplex red 2020European journal of medicinal chemistry, Sep-15, Volume: 202Design, synthesis and biological evaluation of rasagiline-clorgyline hybrids as novel dual inhibitors of monoamine oxidase-B and amyloid-β aggregation against Alzheimer's disease.
AID1192631Binding affinity to human recombinant microsomal MAO-B by ITC2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID1570051Cytoprotective against H2O2-induced cell death in human U251 cells assessed as increase in cell viability at 100 uM preincubated for 24 hrs followed by H2O2 induction and measured after 1 hr by MTS assay (Rvb = 50%)2019European journal of medicinal chemistry, Oct-15, Volume: 180Design, synthesis and biological evaluation of hydroxypyridinone-coumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer's disease.
AID1663424Antialzheimer activity in scopolamine-induced impairment in ICR mouse assessed as latency time at 15 mg/kg, ip administered once a day for 10 days pretreated with scopolamine for 30 mins and measured at 5th day of training session by Morris water maze tes2020Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12
Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
AID1594618Inhibition of human recombinant MAOA using kynuramine as substrate incubated for 10 mins by UPLC-ESI-MS/MS analysis2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Discovery, synthesis, biological evaluation and molecular docking study of (R)-5-methylmellein and its analogs as selective monoamine oxidase A inhibitors.
AID1190179Inhibition of human recombinant MAO-B using p-tyramine as substrate assessed as H2O2 production after 15 mins by fluorescence assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-β-amyloid (Aβ) aggregation and metal chelation properties against Alzheimer's disease.
AID1279152Reversible inhibition of human recombinant MAO-B assessed as enzyme recovery using p-tyramine substrate at 10 times IC50 preincubated for 30 mins followed by 100 fold dilution by fluorimetric analysis relative to control2016Bioorganic & medicinal chemistry, Apr-01, Volume: 24, Issue:7
Design, synthesis and biological evaluation of novel donepezil-coumarin hybrids as multi-target agents for the treatment of Alzheimer's disease.
AID189940T/C value of compound was measured in rats which are treated with phenobarbital (PB)1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Metabolic depropargylation and its relationship to aldehyde dehydrogenase inhibition in vivo.
AID1847831Antiproliferative activity against human DU-145 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay2021Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24
Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent.
AID1332148Inhibition of human recombinant microsomal MAO-B expressed in baculovirus-infected insect cells using p-tyramine as substrate preincubated for 15 mins followed by substrate addition measured for 20 mins by amplex red assay2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents.
AID1761228Inhibition of human MAO-A preincubated for 5 mins followed by addition of Kynuramine substrate and measured after 30 mins by plate reader method2021European journal of medicinal chemistry, Feb-05, Volume: 2112-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease.
AID1378329Inhibition of recombinant human MAO-B using p-tyramine as substrate preincubated for 15 mins followed by substrate addition measured after 20 mins by amplex red reagent based fluorescence assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
AID1868495Inhibition of DOTL1 (unknown origin) using [3H]SAM and HeLa oligo nucleosomes as substrates at 100 uM incubated for 1 hr relative to control2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1528914Inhibition of recombinant human microsomal MAOB expressed in baculovirus infected BTI insect cells using p-tyramine as substrate preincubated for 15 mins followed by substrate addition and measured over 20 mins by amplex red reagent-based horseradish pero
AID114157Antidepressant activity was evaluated by measuring its ability to antagonize reserpine-induced ptosis in mice1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID289284Inhibition of rat liver MAOA after 60 mins pre-incubation2007Bioorganic & medicinal chemistry, Sep-01, Volume: 15, Issue:17
A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics.
AID1190183Irreversible inhibition of human MAO-B at 2 times IC50 using p-tyramine as substrate assessed as H2O2 production after 0 to 60 mins2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-β-amyloid (Aβ) aggregation and metal chelation properties against Alzheimer's disease.
AID751624Inhibition of human recombinant monoamine oxidase-A assessed as kynuramine conversion to 6-hydroxyquinoline after 20 mins by fluorescence spectrophotometric analysis2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Inhibition of monoamine oxidase by phthalide analogues.
AID1378341Hepatotoxicity in Kunming mouse at 2.4 mmol/kg, po administered as single dose via gavage measured continuously for first 4 hrs, intermittently for next 24 hrs and occasionally thereafter for 14 days by microscopic method2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
AID1416359Selectivity index, ratio of IC50 for equine serum BuChE to IC50 for electric eel AChE2017MedChemComm, Jul-01, Volume: 8, Issue:7
Synthesis and pharmacological evaluation of multi-functional homoisoflavonoid derivatives as potent inhibitors of monoamine oxidase B and cholinesterase for the treatment of Alzheimer's disease.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1694875Inhibition of recombinant human MAO-B using p-tyramine as substrate preincubated with enzyme for 15 mins followed incubation with substrate for 20 mins by Amplex red reagent based fluorescence based analysis2020RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2
Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
AID1365631Inhibition of human MAO-B using p-tyramine as substrate preincubated for 15 mins followed by substrate addition measured after 20 mins by fluorescence-based Amplex Red MAO assay2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
Design, synthesis, and evaluation of salicyladimine derivatives as multitarget-directed ligands against Alzheimer's disease.
AID1556049Inhibition of electric eel AChE assessed as reduction in production of H202 using acetylcholine as substrate incubated for 15 mins followed by substrate addition by horse radish peroxidase/Amplex red reagent based fluorescence assay2019European journal of medicinal chemistry, Sep-01, Volume: 177Dipropargyl substituted diphenylpyrimidines as dual inhibitors of monoamine oxidase and acetylcholinesterase.
AID1347961Inhibition of recombinant human MAOA using p-tyramine as substrate preincubated for 15 mins followed by substrate addition measured after 15 mins by Amplex red reagent based fluorescence assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID729969Inhibition of electric eel AChE using acetylthiocholine chloride as substrate after 15 mins by Ellman's method2013European journal of medicinal chemistry, Apr, Volume: 62A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.
AID1663415Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate at 100 nM incubated for 10 mins followed by substrate addition by fluorimetric analysis relative to control2020Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12
Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
AID1528915Selectivity ratio of IC50 for recombinant human microsomal MAOA expressed in baculovirus infected BTI insect cells to IC50 for recombinant human microsomal MAOB expressed in baculovirus infected BTI insect cells
AID1365629Inhibition of self-induced aggregation of amyloid beta (1 to 42 residues) (unknown origin) at 25 uM incubated for 48 hrs by Thioflavin T fluorescence assay relative to control2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
Design, synthesis, and evaluation of salicyladimine derivatives as multitarget-directed ligands against Alzheimer's disease.
AID1649992Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells assessed as reduction in formation of 4-quinolinol using kynuramine as substrate preincubated with substrate for 10 mins followed by enzyme addition and measured afte2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Synthesis of natural product-like polyprenylated phenols and quinones: Evaluation of their neuroprotective activities.
AID1589018Inhibition of 6x-His-tagged and SUMO tagged human PYCR1 expressed in Escherichia coli BL21 (DE3) cells assessed as reduction in NADH oxidation incubated for 1 hr2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
A fragment-like approach to PYCR1 inhibition.
AID410878Inhibition of MAOA in rat liver homogenates preincubated for 60 mins2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
Pyrazoline-based mycobactin analogues as MAO-inhibitors.
AID434137Inhibition of MAOB2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Knowledge based identification of MAO-B selective inhibitors using pharmacophore and structure based virtual screening models.
AID1868502Inhibition of PRMT1 (unknown origin) using [3H]SAM and chicken histone 4 as substrates incubated for 1 hr2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1891689Inhibition of human recombinant MAOB using kynuramine substrate incubated for 20 mins by fluorescence spectrophotometry2022Bioorganic & medicinal chemistry letters, 07-01, Volume: 67The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
AID34055Evaluated in vivo for inhibition of liver mitochondrial aldehyde dehydrogenase activity 2 hour after administering into 5 to 8 rats, and percentage of activity remaining was reported at a concentration of 1.25 mmol/Kg1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Latent inhibitors of aldehyde dehydrogenase as alcohol deterrent agents.
AID1416356Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 5 mins followed by substrate addition measured at 1 to 3 mins time interval by Ellman's method2017MedChemComm, Jul-01, Volume: 8, Issue:7
Synthesis and pharmacological evaluation of multi-functional homoisoflavonoid derivatives as potent inhibitors of monoamine oxidase B and cholinesterase for the treatment of Alzheimer's disease.
AID1373684Inhibition of human recombinant MAOB assessed as residual enzyme activity at 2 time IC50 pre-incubated for 30 mins followed by 0.06 mM benzylamine substrate addition2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Selective inhibition of monoamine oxidase A by hispidol.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1632838Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells preincubated for 10 mins followed by addition of kynuramine as substrate2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Potent selective monoamine oxidase B inhibition by maackiain, a pterocarpan from the roots of Sophora flavescens.
AID116717Acute cytotoxicity was evaluated as LD50 in mice (ip)1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID34052Evaluated in vitro for inhibition of mitochondrial aldehyde dehydrogenase activity in intact rat liver mitochondria (1.0 mM)1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Latent inhibitors of aldehyde dehydrogenase as alcohol deterrent agents.
AID1589019Inhibition of PYCR1 in human SUM159PT cells assessed as reduction proline content at 100 uM by LC-MS analysis relative to control2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
A fragment-like approach to PYCR1 inhibition.
AID1373671Inhibition of human recombinant MAOA using kynuramine as substrate preincubated for 30 mins followed by substrate addition2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Selective inhibition of monoamine oxidase A by hispidol.
AID346980Inhibition of MAO-A in rat liver homogenate after 60 mins by residual activity plot2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity.
AID771513Inhibition of MAOA (unknown origin) using kynuramine as substrate after 1 hr by fluorescence assay2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity.
AID1868498Inhibition of SETD8 (unknown origin) using [3H]SAM and HeLa nucleosomes as substrates incubated for 1 hr2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1378330Selectivity index, ratio of IC50 for recombinant human MAO-A to IC50 for recombinant human MAO-B2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
AID1868497Inhibition of SETD8 (unknown origin) using [3H]SAM and HeLa nucleosomes as substrates at 100 uM incubated for 1 hr relative to control2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1378339Acute toxicity in Kunming mouse assessed as abnormal change in body weight at 2.4 mmol/kg, po administered as single dose via gavage measured continuously for first 4 hrs, intermittently for next 24 hrs and occasionally thereafter for 14 days2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
AID1868506Inhibition of human MAO-B using p-tyramine as substrate by fluorimetric analysis2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1589020Effect on phenylalanine content in human SUM159PT cells at 100 uM by LC-MS analysis relative to control2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
A fragment-like approach to PYCR1 inhibition.
AID1891692Inhibition of human recombinant MAOA assessed as enzyme activity recovery level using kynuramine substrate incubated for 15 mins followed by 24 hrs dialysis by fluorescence spectrophotometry2022Bioorganic & medicinal chemistry letters, 07-01, Volume: 67The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
AID410880Inhibition of rat liver monoamine oxidase by Lineweaver-Burke plot2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
Pyrazoline-based mycobactin analogues as MAO-inhibitors.
AID1378876Irreversible inhibition of recombinant human MAO-B assessed as enzyme activity recovery at 10 times IC50 using p-tyramine as substrate preincubated for 30 mins followed by 100 fold compound dilution by Amplex Red dye-based fluorometric method relative to 2017European journal of medicinal chemistry, Oct-20, Volume: 139Design, synthesis and biological evaluation of novel coumarin-N-benzyl pyridinium hybrids as multi-target agents for the treatment of Alzheimer's disease.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1347963Inhibition of recombinant human MAOB using benzylamine as substrate preincubated for 15 mins followed by substrate addition measured after 15 mins by Amplex red reagent based fluorescence assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1663425Antialzheimer activity in scopolamine-induced impairment in ICR mouse assessed as total distance to platform at 15 mg/kg, ip administered once a day for 10 days pretreated with scopolamine for 30 mins and measured at 5th day of training session by Morris 2020Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12
Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
AID1378338Acute toxicity in Kunming mouse assessed as abnormal change in food consumption at 2.4 mmol/kg, po administered as single dose via gavage measured continuously for first 4 hrs, intermittently for next 24 hrs and occasionally thereafter for 14 days2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
AID1416357Inhibition of equine serum BuChE using S-butyrylthiocholine iodide as substrate preincubated for 5 mins followed by substrate addition measured at 1 to 3 mins time interval by Ellman's method2017MedChemComm, Jul-01, Volume: 8, Issue:7
Synthesis and pharmacological evaluation of multi-functional homoisoflavonoid derivatives as potent inhibitors of monoamine oxidase B and cholinesterase for the treatment of Alzheimer's disease.
AID1868504Inhibition of human MAO-A using p-tyramine as substrate by fluorimetric analysis2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1201753Reversible inhibition of human MAO-B at 10 times IC50 incubated for 30 mins followed by 100 fold dilution to 0.1 times IC50 by dilution assay relative to control2015European journal of medicinal chemistry, May-05, Volume: 95Multi-target tacrine-coumarin hybrids: cholinesterase and monoamine oxidase B inhibition properties against Alzheimer's disease.
AID1119188Inhibition of LSD1 (unknown origin) at 10 uM relative to control2012MedChemComm, , Volume: 3, Issue:1
Polyamine-based small molecule epigenetic modulators.
AID1416361Inhibition of recombinant human MAO-A assessed as reduction in H2O2 production using p-tyramine as substrate preincubated for 15 mins followed by substrate addition by Amplex red reagent based fluorescence assay2017MedChemComm, Jul-01, Volume: 8, Issue:7
Synthesis and pharmacological evaluation of multi-functional homoisoflavonoid derivatives as potent inhibitors of monoamine oxidase B and cholinesterase for the treatment of Alzheimer's disease.
AID1209456Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID34019Percent inhibition of the enzyme Alcohol dehydrogenase was measured in rats which are treated with phenobarbital (PB)1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Metabolic depropargylation and its relationship to aldehyde dehydrogenase inhibition in vivo.
AID1132602Inhibition of MAO in mouse brain using serotonin as substrate1978Journal of medicinal chemistry, Apr, Volume: 21, Issue:4
2-(Alkoxyaryl)-2-imidazoline monoamine oxidase inhibitors with antidepressant activity.
AID1373686Irreversible inhibition of human recombinant MAOB assessed as residual enzyme activity at 2 time IC50 pre-incubated for 30 mins followed by 0.06 mM benzylamine substrate addition2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Selective inhibition of monoamine oxidase A by hispidol.
AID34050Evaluated in vitro for inhibition of mitochondrial aldehyde dehydrogenase (AIDH) activity in intact rat liver mitochondria (0.2 mM)1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Latent inhibitors of aldehyde dehydrogenase as alcohol deterrent agents.
AID1056994Irreversible inhibition of human recombinant MAO-B at 200 nM preincubated for 15 mins followed by repeated washing by centrifugation-ultrafiltration method relative to control2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
AID496772Modulation of neurological behavior in zebrafish assessed as effect on touch response by high-throughput screening2010Nature chemical biology, Mar, Volume: 6, Issue:3
Rapid behavior-based identification of neuroactive small molecules in the zebrafish.
AID1570054Cognition enhancement in scopolamine-induced impairment in ICR mouse assessed as number of times to enter target quadrant at 10 mg/kg, ip administered once daily for 2 weeks pretreated with scopolamine for 30 mins and measured at 5th day of training sessi2019European journal of medicinal chemistry, Oct-15, Volume: 180Design, synthesis and biological evaluation of hydroxypyridinone-coumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer's disease.
AID1365632Selectivity index, ratio of IC50 for human MAO-A to IC50 for human MAO-B2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
Design, synthesis, and evaluation of salicyladimine derivatives as multitarget-directed ligands against Alzheimer's disease.
AID1694872Inhibition of equine serum BuChE using butyrylthiocholine iodide as substrate preincubated with enzyme for 6 mins followed by substrate addition and measured for 180 secs by Ellman's method2020RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2
Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
AID383160Inhibition of monoamine oxidase B at 10 uM2008Journal of natural products, May, Volume: 71, Issue:5
Xanthones from Gentianella amarella ssp. acuta with acetylcholinesterase and monoamine oxidase inhibitory activities.
AID751612Irreversible inhibition of human recombinant monoamine oxidase-A using kynuramine as substrate assessed as residual enzyme activity treated at 10 times IC50 preincubated for 30 mins prior to substrate addition followed by 100 fold dilution measured after 2013Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5
Inhibition of monoamine oxidase by phthalide analogues.
AID173004Blood AcH level of compound was measured in rats which are treated with phenobarbital (PB)1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Metabolic depropargylation and its relationship to aldehyde dehydrogenase inhibition in vivo.
AID1416362Selectivity index, ratio of IC50 for recombinant human MAO-A to IC50 for recombinant human MAO-B2017MedChemComm, Jul-01, Volume: 8, Issue:7
Synthesis and pharmacological evaluation of multi-functional homoisoflavonoid derivatives as potent inhibitors of monoamine oxidase B and cholinesterase for the treatment of Alzheimer's disease.
AID729967Inhibition of horse serum BChE using butyrylthiocholine chloride as substrate after 15 mins by Ellman's method2013European journal of medicinal chemistry, Apr, Volume: 62A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.
AID1056996Inhibition of human recombinant MAO-B at 200 nM incubated for 15 mins prior to washing relative to control2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
AID749472Induction of adipogenesis in human bone marrow MSC assessed as formation of intracellular lipid droplets at 10 uM after 15 days by oil red O staining in IDX condition relative to control2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
The opposite effect of isotype-selective monoamine oxidase inhibitors on adipogenesis in human bone marrow mesenchymal stem cells.
AID625294Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1057002Inhibition of human recombinant MAO-B using benzylamine as substrate preincubated for 15 mins under dark condition followed by substrate addition measured after 20 mins by fluorescence assay2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
AID1230944Inhibition of human serum BuChE by spectrophotometric Ellman's method2015Journal of medicinal chemistry, Jul-23, Volume: 58, Issue:14
Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.
AID1190178Inhibition of human recombinant MAO-A using p-tyramine as substrate assessed as H2O2 production at 100 uM after 15 mins by fluorescence assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-β-amyloid (Aβ) aggregation and metal chelation properties against Alzheimer's disease.
AID410879Inhibition of MAOB in rat liver homogenates preincubated for 60 mins2008Bioorganic & medicinal chemistry letters, Dec-15, Volume: 18, Issue:24
Pyrazoline-based mycobactin analogues as MAO-inhibitors.
AID1231604Antioxidant activity assessed as trolox equivalent of AAPH radical scavenging activity compound preincubated for 10 mins followed by AAPH challenge measured every min for 120 mins by ORAC-FL assay2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer's disease.
AID1378337Acute toxicity in Kunming mouse assessed as abnormal change in water consumption at 2.4 mmol/kg, po administered as single dose via gavage measured continuously for first 4 hrs, intermittently for next 24 hrs and occasionally thereafter for 14 days2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
AID1589021Effect on methionine content in human SUM159PT cells at 100 uM by LC-MS analysis relative to control2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
A fragment-like approach to PYCR1 inhibition.
AID1570043Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells incubated for 15 mins with substrate p-Tyramine by fluorescence assay2019European journal of medicinal chemistry, Oct-15, Volume: 180Design, synthesis and biological evaluation of hydroxypyridinone-coumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer's disease.
AID1651632Inhibition of recombinant human MAO-B at 10 uM incubated for 30 mins by fluorescence-based method2020Journal of natural products, 04-24, Volume: 83, Issue:4
Bioactive Azepine-Indole Alkaloids from
AID1761229Inhibition of human MAO-B preincubated for 5 mins followed by addition of Kynuramine substrate and measured after 30 mins by plate reader method2021European journal of medicinal chemistry, Feb-05, Volume: 2112-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease.
AID1626716Inhibition of human recombinant MAOB expressed in microsomes of baculovirus-infected insect cell using kynuramine as substrate preincubated for 20 mins followed by protein addition measured after 30 mins by fluorescence assay2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.
AID188352The enzymatic formation of propionaldehyde from compound on inhibition with rat liver microsomes in the presence of an NADPH (treated with phenobarbital (PB))1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Metabolic depropargylation and its relationship to aldehyde dehydrogenase inhibition in vivo.
AID1192622Inhibition of human recombinant soluble MAO-B expressed in Pichia pastoris incubated for 30 mins prior to substrate addition measured after 60 mins by MAO-Glo assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID1868499Inhibition of EZH2 (unknown origin) using [3H]SAM and chicken core histone as substrates at 100 uM incubated for 1 hr relative to control2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1209457Unbound Cmax in human plasma2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1651633Inhibition of recombinant human MAO-A incubated for 30 mins by fluorescence-based method2020Journal of natural products, 04-24, Volume: 83, Issue:4
Bioactive Azepine-Indole Alkaloids from
AID1826386Irreversible inhibition of human recombinant MAO-B expressed in supersomes using kynuramine as substrate at 100 nM preincubated with enzyme for 1 hr and measured over 6 hrs by spectrophotometric method
AID346979Inhibition of MAO-B in rat liver homogenate after 60 mins by residual activity plot2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity.
AID1571214Inhibition of MAOA (unknown origin) using kynuramine as substrate preincubated for 30 mins followed by substrate addition2018MedChemComm, Nov-01, Volume: 9, Issue:11
Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors.
AID1373672Inhibition of human recombinant MAOB using benzylamine as substrate preincubated for 30 mins followed by substrate addition2018Bioorganic & medicinal chemistry letters, 02-15, Volume: 28, Issue:4
Selective inhibition of monoamine oxidase A by hispidol.
AID173005Blood AcH level of compound was measured in rats which are untreated with phenobarbital (PB)1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Metabolic depropargylation and its relationship to aldehyde dehydrogenase inhibition in vivo.
AID289285Inhibition of rat liver MAOB after 60 mins pre-incubation2007Bioorganic & medicinal chemistry, Sep-01, Volume: 15, Issue:17
A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics.
AID1570052Cognition enhancement in scopolamine-induced impairment in ICR mouse assessed as latency time at 10 mg/kg, ip administered once daily for 2 weeks pretreated with scopolamine for 30 mins and measured at 5th day of training session by Morris water maze test2019European journal of medicinal chemistry, Oct-15, Volume: 180Design, synthesis and biological evaluation of hydroxypyridinone-coumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer's disease.
AID1319664Inhibition of recombinant human MAO-A using kynuramine as substrate after 20 mins2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
2-Benzylidene-1-indanone derivatives as inhibitors of monoamine oxidase.
AID346981Inhibition of MAO-A in rat liver homogenate after 60 mins by Lineweaver-Burke plot2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity.
AID1868501Inhibition of PRMT1 (unknown origin) using [3H]SAM and chicken histone 4 as substrates at 100 uM incubated for 1 hr relative to control2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1694871Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated with enzyme for 6 mins followed by substrate addition and measured for 180 secs by Ellman's method2020RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2
Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
AID383159Inhibition of monoamine oxidase A at 10 uM2008Journal of natural products, May, Volume: 71, Issue:5
Xanthones from Gentianella amarella ssp. acuta with acetylcholinesterase and monoamine oxidase inhibitory activities.
AID729961Irreversible inhibition of recombinant human MAO-B using p-tyramine substrate preincubated at 200 nM for 15 mins before substrate addition measured after repeated wash-out by fluorescence assay2013European journal of medicinal chemistry, Apr, Volume: 62A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.
AID1484655Irreversible inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cell microsomes assessed as residual activity using kynuramine as substrate at 13 uM preincubated for 15 mins with subsequent dialysis for 24 hrs followed by s2017European journal of medicinal chemistry, Jul-28, Volume: 135The evaluation of 1,4-benzoquinones as inhibitors of human monoamine oxidase.
AID1347966Antioxidant activity assessed as trolox equivalent of AAPH radical scavenging activity preincubated for 10 mins followed by AAPH addition measured every 2 mins for 180 mins by ORAC-FL assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.
AID1624338Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI insect cells using benzylamine as substrate after 30 mins by spectrophotometric analysis2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity.
AID1378328Inhibition of recombinant human MAO-A using p-tyramine as substrate preincubated for 15 mins followed by substrate addition measured after 20 mins by amplex red reagent based fluorescence assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
AID1651628Inhibition of electric eel AchE using acetylthiocholine as substrate at 10 uM measured for 6 mins by Ellman's method2020Journal of natural products, 04-24, Volume: 83, Issue:4
Bioactive Azepine-Indole Alkaloids from
AID771522Inhibition of MAOB (unknown origin) using kynuramine as substrate after 1 hr by fluorescence assay2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity.
AID1594619Inhibition of human recombinant MAOB using kynuramine as substrate incubated for 10 mins by UPLC-ESI-MS/MS analysis2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Discovery, synthesis, biological evaluation and molecular docking study of (R)-5-methylmellein and its analogs as selective monoamine oxidase A inhibitors.
AID1571230Irreversible inhibition of MAOB (unknown origin) assessed as residual enzyme activity at 0.2 uM using benzylamine as substrate pre-incubated for 30 mins followed by dialysis with pH 7.2 sodium phosphate buffer relative to control2018MedChemComm, Nov-01, Volume: 9, Issue:11
Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors.
AID729962Irreversible inhibition of recombinant human MAO-B using p-tyramine substrate preincubated at 200 nM for 15 mins before substrate addition measured after 20 mins by fluorescence assay2013European journal of medicinal chemistry, Apr, Volume: 62A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.
AID188353The enzymatic formation of propionaldehyde from compound on inhibition with rat liver microsomes in the presence of an NADPH (untreated with phenobarbital (PB))1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Metabolic depropargylation and its relationship to aldehyde dehydrogenase inhibition in vivo.
AID1378340Cardiotoxicity in Kunming mouse at 2.4 mmol/kg, po administered as single dose via gavage measured continuously for first 4 hrs, intermittently for next 24 hrs and occasionally thereafter for 14 days by microscopic method2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
AID1694886Irreversible inhibition of human recombinant MAO-B assessed as residual enzyme activity using p-tyramine as substrate preincubated with enzyme for 30 mins at 10-100XIC50 followed by 100-fold dilution to 0.1-10XIC50 followed by incubation with substrate fo2020RSC medicinal chemistry, Feb-01, Volume: 11, Issue:2
Chromone and donepezil hybrids as new multipotent cholinesterase and monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease.
AID1209455Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake2012Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 40, Issue:1
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
AID1571215Inhibition of MAOB (unknown origin) using benzylamine as substrate preincubated for 30 mins followed by substrate addition2018MedChemComm, Nov-01, Volume: 9, Issue:11
Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors.
AID1124439Induction of ethanol-derived blood acetaldehyde level in 0.1% phenobarbital for 8 days pretreated Sprague-Dawley rat measured after 2 hrs of acute ethanol dose1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Propiolaldehyde, a pargyline metabolite that irreversibly inhibits aldehyde dehydrogenase. Isolation from a hepatic microsomal system.
AID1639479Inhibition of Wistar rat brain MAOB using kynuramine as substrate preincubated for 15 mins followed by substrate addition and measured after 15 mins by fluorescence assay
AID1230939Inhibition of human recombinant MAO-B using kynuramine substrate by spectrophotometric assay2015Journal of medicinal chemistry, Jul-23, Volume: 58, Issue:14
Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.
AID34020Percent inhibition of the enzyme Alcohol dehydrogenase was measured in rats which are untreated with phenobarbital (PB)1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Metabolic depropargylation and its relationship to aldehyde dehydrogenase inhibition in vivo.
AID1754859Inhibition of human recombinant MAO-B using kynuramine as substrate incubated for 20 mins measuring increase in emission signal at 400 nm multimode plate reader assay2021Bioorganic & medicinal chemistry, 07-15, Volume: 42Synthesis and biological evaluation of 3-styrylchromone derivatives as selective monoamine oxidase B inhibitors.
AID1230942Inhibition of human recombinant AChE by spectrophotometric Ellman's method2015Journal of medicinal chemistry, Jul-23, Volume: 58, Issue:14
Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.
AID1378344Acute toxicity in Kunming mouse assessed as effect on serum ALT level at 2.4 mmol/kg, po administered as single dose via gavage measured continuously for first 4 hrs, intermittently for next 24 hrs and occasionally thereafter for 14 days2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
AID1378331Irreversible inhibition of recombinant human MAO-B at 200 nM using p-tyramine as substrate preincubated for 15 to 60 mins followed by substrate addition and subsequent two-fold enzyme dilution measured after 15 mins by amplex red reagent based fluorescenc2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
AID771524Inhibition of LSD1 (unknown origin) expressed in Sf9 cells using H3K4(me2) as substrate at 100 uM preincubated for 30 mins prior to substrate addition measured after 90 mins by horseradish peroxidase assay relative to control2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Nonpeptidic propargylamines as inhibitors of lysine specific demethylase 1 (LSD1) with cellular activity.
AID1891690Selectivity index, ratio of IC50 for inhibition of human recombinant MAOA to IC50 for human recombinant MAOB2022Bioorganic & medicinal chemistry letters, 07-01, Volume: 67The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
AID224595Inhibition of the enzyme Alcohol dehydrogenase was measured in rats which are treated with phenobarbital (PB)1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Metabolic depropargylation and its relationship to aldehyde dehydrogenase inhibition in vivo.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1868496Inhibition of DOTL1 (unknown origin) using [3H]SAM and HeLa oligo nucleosomes as substrates incubated for 1 hr2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1332149Inhibition of human recombinant BuChe using butyrylthiocholine as substrate preincubated for 5 mins followed by substrate addition measured for 1 min by Ellman's method2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents.
AID1528913Inhibition of recombinant human microsomal MAOA expressed in baculovirus infected BTI insect cells using p-tyramine as substrate preincubated for 15 mins followed by substrate addition and measured over 20 mins by amplex red reagent-based horseradish pero
AID1761230Selectivity index, ratio of IC50 for human MAO-A to IC50 for human MAO-B using Kynuramine as substrate measured by plate reader method2021European journal of medicinal chemistry, Feb-05, Volume: 2112-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease.
AID1589034Inhibition of PYCR1 in human SUM159PT cells assessed as reduction proline content by LC-MS analysis relative to control2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
A fragment-like approach to PYCR1 inhibition.
AID1231601Inhibition of human recombinant MAO-A using p-tyramine as substrate incubated for 15 mins prior to substrate addition measured after 20 mins by fluorescence plate reader analysis2015Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer's disease.
AID1332152Selectivity ratio of IC50 for human recombinant microsomal MAO-A expressed in baculovirus-infected insect cells to IC50 for human recombinant microsomal MAO-B expressed in baculovirus-infected insect cells2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents.
AID1378343Acute toxicity in Kunming mouse assessed as effect on serum AST level at 2.4 mmol/kg, po administered as single dose via gavage measured continuously for first 4 hrs, intermittently for next 24 hrs and occasionally thereafter for 14 days2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
AID1365630Inhibition of human MAO-A using p-tyramine as substrate preincubated for 15 mins followed by substrate addition measured after 20 mins by fluorescence-based Amplex Red MAO assay2017Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
Design, synthesis, and evaluation of salicyladimine derivatives as multitarget-directed ligands against Alzheimer's disease.
AID114156Antidepressant activity was evaluated by measuring its ability to antagonize RO 4-1284-induced hypothermia in mice1988Journal of medicinal chemistry, Jun, Volume: 31, Issue:6
2,4-Dihydro-3H-1,2,4-triazole-3-thiones as potential antidepressant agents.
AID254307Inhibition constant against human recombinant Monoamine oxidase-B 2005Bioorganic & medicinal chemistry letters, Oct-15, Volume: 15, Issue:20
Docking studies on monoamine oxidase-B inhibitors: estimation of inhibition constants (K(i)) of a series of experimentally tested compounds.
AID1571216Selectivity index, ratio of IC50 for MAOA (unknown origin) to IC50 for MAOB (unknown origin)2018MedChemComm, Nov-01, Volume: 9, Issue:11
Selected aryl thiosemicarbazones as a new class of multi-targeted monoamine oxidase inhibitors.
AID1754857Selectivity index, ratio of IC50 for recombinant human MAO-A to IC50 for recombinant human MAO-B2021Bioorganic & medicinal chemistry, 07-15, Volume: 42Synthesis and biological evaluation of 3-styrylchromone derivatives as selective monoamine oxidase B inhibitors.
AID1192634Inhibition of human recombinant soluble MAO-B assessed as change in melting temperature at 10 uM after 20 mins by SYPRO orange staining-based fluorescence assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID346978Inhibition of MAO-B in rat liver homogenate after 60 mins by Lineweaver-Burke plot2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity.
AID1624340Competitive inhibition of human recombinant MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 20 mins by Lineweaver-Burk plot analysis2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity.
AID1378342Nephrotoxicity in Kunming mouse at 2.4 mmol/kg, po administered as single dose via gavage measured continuously for first 4 hrs, intermittently for next 24 hrs and occasionally thereafter for 14 days by microscopic method2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
AID1626714Inhibition of human recombinant MAOA expressed in microsomes of baculovirus-infected insect cell using kynuramine as substrate preincubated for 20 mins followed by protein addition measured after 30 mins by fluorescence assay2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
Exploring Basic Tail Modifications of Coumarin-Based Dual Acetylcholinesterase-Monoamine Oxidase B Inhibitors: Identification of Water-Soluble, Brain-Permeant Neuroprotective Multitarget Agents.
AID1332150Inhibition of mouse AChe using acetylthiocholine as substrate preincubated for 5 mins followed by substrate addition measured for 1 min by Ellman's method2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents.
AID1190181Inhibition of amyloid beta (1 to 42) (unknown origin) self-induced aggregation at 20 uM after 46 to 48 hrs by thioflavin-T fluorescence method2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Multifunctional coumarin derivatives: monoamine oxidase B (MAO-B) inhibition, anti-β-amyloid (Aβ) aggregation and metal chelation properties against Alzheimer's disease.
AID1624337Inhibition of human recombinant MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 20 mins by spectrophotometric analysis2019Bioorganic & medicinal chemistry letters, 03-15, Volume: 29, Issue:6
Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity.
AID1632839Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells preincubated for 10 mins followed by addition of benzylamine as substrate2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
Potent selective monoamine oxidase B inhibition by maackiain, a pterocarpan from the roots of Sophora flavescens.
AID1594620Selectivity index, ratio of IC50 for human recombinant MAOB to IC50 for human recombinant MAOA2019Bioorganic & medicinal chemistry, 05-15, Volume: 27, Issue:10
Discovery, synthesis, biological evaluation and molecular docking study of (R)-5-methylmellein and its analogs as selective monoamine oxidase A inhibitors.
AID1378346Inhibition of MAO-B (unknown origin)2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
AID1769259Inhibition of BCRP (unknown origin) transfected in HEK293/R2 cells assessed as reversal of topotecan resistance after 5 days by MTS/PMS assay2021Journal of medicinal chemistry, 10-14, Volume: 64, Issue:19
Flavonoid Monomers as Potent, Nontoxic, and Selective Modulators of the Breast Cancer Resistance Protein (ABCG2).
AID1319665Irreversible inhibition of recombinant human MAO-A assessed as residual activity pre-incubated at 4 times IC50 for 15 mins followed by dialysis for 24 hrs and subsequent kynuramine addition measured after 20 mins by fluorescence spectrophotometric analysi2016Bioorganic & medicinal chemistry letters, 10-01, Volume: 26, Issue:19
2-Benzylidene-1-indanone derivatives as inhibitors of monoamine oxidase.
AID1589025Effect on isoleucine content in human SUM159PT cells at 100 uM by LC-MS analysis relative to control2019Bioorganic & medicinal chemistry letters, 09-15, Volume: 29, Issue:18
A fragment-like approach to PYCR1 inhibition.
AID1332147Inhibition of human recombinant microsomal MAO-A expressed in baculovirus-infected insect cells using p-tyramine as substrate preincubated for 15 mins followed by substrate addition measured for 20 mins by amplex red assay2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
N-Propargylpiperidines with naphthalene-2-carboxamide or naphthalene-2-sulfonamide moieties: Potential multifunctional anti-Alzheimer's agents.
AID1663416Inhibition of human recombinant MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate incubated for 10 mins followed by substrate addition by fluorimetric analysis2020Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12
Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity.
AID1057004Inhibition of human recombinant MAO-A using p-tyramine as substrate assessed as formation of H2O2 at 100 uM preincubated for 15 mins under dark condition followed by substrate addition measured after 20 mins by fluorescence assay relative to control2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine-Homoisoflavonoid hybrids.
AID1378336Acute toxicity in Kunming mouse assessed as mortality at 2.4 mmol/kg, po administered as single dose via gavage measured continuously for first 4 hrs, intermittently for next 24 hrs and occasionally thereafter for 14 days2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
AID1192621Inhibition of human recombinant microsomal MAO-B expressed in Pichia pastoris incubated for 30 mins prior to substrate addition measured after 60 mins by MAO-Glo assay2015Bioorganic & medicinal chemistry, Feb-15, Volume: 23, Issue:4
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
AID1556048Inhibition of human recombinant microsomal MAO-A expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as reduction in production of H202 using p-tyramine as substrate incubated for 30 mins followed by substrate addition by horse radish peroxidase2019European journal of medicinal chemistry, Sep-01, Volume: 177Dipropargyl substituted diphenylpyrimidines as dual inhibitors of monoamine oxidase and acetylcholinesterase.
AID1278141Reversible inhibition of recombinant human MAO-A assessed as enzyme activity recovered pretreated with compound for 15 mins followed by addition of 50 uM kynuramine as substrate measured after 24 hrs by dialysis2016Bioorganic & medicinal chemistry letters, Feb-15, Volume: 26, Issue:4
Inhibition of monoamine oxidase by benzoxathiolone analogues.
AID1847828Antiproliferative activity against human PC-3 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay2021Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24
Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent.
AID1230937Inhibition of human recombinant MAO-A using kynuramine substrate by spectrophotometric assay2015Journal of medicinal chemistry, Jul-23, Volume: 58, Issue:14
Structure-Based Design and Optimization of Multitarget-Directed 2H-Chromen-2-one Derivatives as Potent Inhibitors of Monoamine Oxidase B and Cholinesterases.
AID1556047Inhibition of human recombinant microsomal MAO-B expressed in baculovirus infected BTI-TN-5B1-4 cells assessed as reduction in production of H202 using p-tyramine as substrate incubated for 30 mins followed by substrate addition by horse radish peroxidase2019European journal of medicinal chemistry, Sep-01, Volume: 177Dipropargyl substituted diphenylpyrimidines as dual inhibitors of monoamine oxidase and acetylcholinesterase.
AID1378345Inhibition of MAO-A (unknown origin)2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and evaluation of coumarin-pargyline hybrids as novel dual inhibitors of monoamine oxidases and amyloid-β aggregation for the treatment of Alzheimer's disease.
AID729965Inhibition of recombinant human MAO-B using p-benzylamine substrate preincubated for 15 mins before substrate addition measured after 20 mins by fluorescence assay2013European journal of medicinal chemistry, Apr, Volume: 62A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer's disease.
AID34053Evaluated in vivo for inhibition of liver mitochondrial aldehyde dehydrogenase activity 2 hour after administering into 5 to 8 rats, at a dose of 1.25 mmol/kg1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
Latent inhibitors of aldehyde dehydrogenase as alcohol deterrent agents.
AID1868500Inhibition of EZH2 (unknown origin) using [3H]SAM and chicken core histone as substrates incubated for 1 hr2022European journal of medicinal chemistry, Jul-05, Volume: 237Novel non-covalent LSD1 inhibitors endowed with anticancer effects in leukemia and solid tumor cellular models.
AID1891688Inhibition of human recombinant MAOA using kynuramine substrate incubated for 20 mins by fluorescence spectrophotometry2022Bioorganic & medicinal chemistry letters, 07-01, Volume: 67The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1345941Rat Monoamine oxidase B (Catecholamine turnover)1982Biochemical pharmacology, Nov-15, Volume: 31, Issue:22
The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,693)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901846 (68.55)18.7374
1990's336 (12.48)18.2507
2000's185 (6.87)29.6817
2010's273 (10.14)24.3611
2020's53 (1.97)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 35.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index35.23 (24.57)
Research Supply Index7.95 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index54.33 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (35.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials27 (0.96%)5.53%
Reviews74 (2.63%)6.00%
Case Studies10 (0.36%)4.05%
Observational0 (0.00%)0.25%
Other2,700 (96.05%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]